Trial Profile
An Observational Cross-sectional Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary)
- Indications Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
- Focus Therapeutic Use
- Acronyms B Part of It
- 06 Sep 2021 Status has been changed to completed, as per published in the Journal of Infectious Diseases
- 06 Sep 2021 Primary endpoint has not been met. (Carriage prevalence of disease causing genogroups of N.meningitidis (A, B, C, W, X, Y) in South Australian school leavers), as per published in the Journal of Infectious Diseases
- 06 Sep 2021 Results from repeat cross-sectional B Part of It School Leaver study, assessing impact of increasing coverage with 4CMenB vaccine on carriage of Neisseria meningitidis, published in the Journal of Infectious Diseases